ArticleRSC advances2025
Covalent modification of iron oxide-poly(lithocholic acid) nanoparticles with folic acid or doxorubicin - an approach for enhanced cancer therapy.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mesoporous silica nanoparticles with an azobenzene gatekeeper as hypoxia-responsive nanocarriers for targeted doxorubicin delivery.Drug delivery and translational research · 2026Article
- Nanoparticles for Doxorubicin Delivery: Advances in Carrier Design and Synergistic Cancer Therapy.Topics in current chemistry (Cham) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explores the effectiveness against selected cancer cell lines of nano-engineered formulations composed of inorganic cores with steroid-based polymeric shells functionalized with either a targeting or chemotherapeutic agent. We present the synthesis and comprehensive characterization of iron oxide nanoparticles coated by polymeric layers derived from lithocholic acid with covalently affixed folic acid or doxorubicin entities. The cytotoxicity assessments against normal (RBCs, THP-1, CCD-1079sk, and H9C2(2-1) and cancerous (MCF-7, MDA-MB-231, and HeLa) cell lines were performed using two independent endpoint (MTT and neural red) assays. In the case of cancer cells, transepithelial electrical resistance (TERR) and caspase 8 and 9 expression were examined. Additionally, the impact on the activity of xenobiotic metabolizing enzymes from the cytochrome family has been assessed. The results of the study confirmed the selectivity of the synthesized hybrids against tested cancer cells and their ability to induce apoptosis
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.